Report Highlights
The total market for advanced wound care reached at $3.4 billion in 2010. It is expected to reach at $3.6 billion in 2011; it will further grow to $4.6 billion by 2016 at a compound annual growth rate (CAGR) of 4.9%.
SCOPE OF REPORT
This document is designed to be a helpful business tool that will provide a thorough evaluation of the advanced wound care market. The scope of this study is U.S. based and identifies markets in five general segments:
- Biological dressings
- Surgical sealants
- Synthetic dressings
- Anti–adhesion products and other related wound healing products
- Wound healing devices
Each market segment provides detailed information based on product categories, product use, forecasts and competitive analyses.
Advanced wound care deals with those products that involve new techniques and therapies, are of benefit in healing wounds and result in overall lower costs for care. They incorporate biotechnological advancements and improved methods for dealing with wounds. Products in this study are considered to be at the forefront of wound care technology.
Traditional wound care products, those that have previously been used in the marketplace, are not addressed in this analysis. Industry experts classify “advanced wound care products” as those that include biological dressings, surgical sealants, synthetic dressings, anti–adhesion products and other related wound–healing products.
ANALYST CREDENTIALS
Tracy Cotthoff is an experienced wound care nurse in a high–volume burn center in Portland, Oregon. Ms. Cotthoff has been in the medical field for over 17 years. This experience has given her a vast knowledge of medical practices and advances in the industry and new technologies. Her experience in the medical field includes EMT training and nursing, including critical care nursing, which has allowed for her substantial insight into the workings of the healthcare industry.
Melissa Elder is an experienced healthcare market analyst specializing in prescription and over–the–counter pharmaceuticals, medical devices, and emerging healthcare technologies. Ms. Elder has nearly 20 years of experience in the healthcare industry, specializing in market research for the past 14 years. This experience has given her a strong understanding of pharmaceutical market analysis. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare markets.
Report Highlights
- The U.S. market for advanced wound care will increase from $3.0 billion in 2007 to an estimated $3.5 billion by the end of 2008. It should reach $6.0 billion in 2013, a compound annual growth rate (CAGR) of 11.7%.
- Wound care dressings, sealants and anti-adhesion products have the largest share of the market, worth $1.7 billion in 2007. This is expected to increase to more than $1.8 billion in 2008 and more than $3.0 billion in 2013, for a CAGR of 10.0%.
- Wound healing devices have the second largest market share, generating $1.3 billion in 2007 and an estimated $1.6 billion in 2008. This should increase at a CAGR of 13.4% to reach $3.0 billion in 2013.
Report Highlights
-
The total U.S. market for advanced wound care technologies was worth more than $2.3 billion in 2005. By the end of 2006 the market will reach almost $2.6 billion, and over a five-year period will grow at an average annual growth rate (AAGR) of 12.3% to reach $4.6 billion in 2011.
-
Wound care dressings, sealants, and antiadhesion products held the largest market share through the forecast period by a small margin, with 59.2% of the total market in 2006. By the end of 2011 the segment will hold 55% of the total U.S. market.
-
Wound healing devices account for a smaller portion of revenues with nearly 1.1 billion in estimated sales for 2006 or 40.8% of revenues. Products in this segment include electrostimulation products, hyperbaric oxygen therapies, vacuum assisted therapies, and other products.
Report Highlights
-
The total U.S. market for advanced wound care was estimated at more than $1.7 billion in 2003 and is expected to rise at an AAGR (average annual growth rate) of 10.2% to $2.8 billion.
-
Biological dressings, surgical sealants, synthetic dressings and other wound healing products account for $1.1 billion and will rise at an AAGR of 7.2%.
-
Wound healing devices, e.g., electrostimulation products, hyperbaric oxygen therapies and vacuum-assisted therapies, account for a smaller portion with $608.2 million in sales but are rising faster at an AAGR of 15%.
Report Highlights
- The total U.S. market for wound care products in 2000 exceeded $2.1 billion. Growing at an average annual rate (AAGR) of 10.1%, this market is forecast to exceed $3.4 billion in 2005.
- The market share for wound closing technologies will rise from 58.7% to over 63% in 2005, as this segment rises at an AAGR of 11.7%.
- At 34%, synthetic dressings represent the second largest market segment, but, growing at an AAGR of 7.1%, will drop to 30% in 2005.
- Biological and biosynthetic dressings will feature the fastest growth, rising at an AAGR of 14.2% during the period.
Related Reports
Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
The global market for healthcare-acquired infection treatments were nearly $16 billion in year 2010. This market is estimated to be around $18.3 billion in the year 2011 and is forecasted to reach $25.6 billion by 2016 at a CAGR of 7.0% for five year period.
Global Markets for Dental Consumables and Prosthetics
The overall value of the global dental consumables and prosthetics market was worth $15.9 billion in 2010, up from $15.7 billion in 2009. The market is estimated to reach $18.5 billion in 2015, at a compound annual growth rate (CAGR) of 3.1% over the forecast period.
Therapeutics for Immune System Disorders
In 2010, the global market for drugs for the treatment of immune disease was estimated to be approximately $72.2 billion. The market size is forecast to grow at a compound annual growth rate (CAGR) of 2.6% to reach $82.2 billion by 2015.
Biologic Therapeutic Drugs: Technologies and Global Markets
The global biologics market is valued at an estimated $149 billion in 2010 and is expected to reach $239 billion by 2015, a compound annual growth rate (CAGR) of 9.9% from 2010-2015. Driving this growth is the need for a more extensive drug pipeline, attractive targets against challenging diseases, a push to pursue biosimilars, and enabling manufacturing technologies that reduce the cost to produce profitable products.
Recent Reports
Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets
The global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.
Rare Disease Diagnostics: Technologies and Global Markets
The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
Softgel Capsules: Global Markets
The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More